Zambon's R&D core competences range from hit-to-lead optimization up to full drug development. Its Lead Optimization Unit is capable to quickly bridge the gap between hit discovery and pre-clinical development and to reduce the risk of failures in clinical development. Zambon's R&D wants to become a valuable partner for all those Drug Discovery companies that want to add value to their lead molecules and see their candidate drugs enter riskless into development.
Companies having proprietary hits/lead compounds for innovative targets or proprietary targets and screening capabilities, will find a dynamic group capable to either optimize existing compounds or discover new hits. Zambon business model is based on collaboration aiming at bringing values to all partners. Roles and responsibilities can be flexibly arranged to obtain a successful and well-balanced relationship among partners.
Dr Salvatore Sturniolo
Licensing Manager
Licensing & Business Development
Zambon Company SpA is a privately-held multinational pharmaceutical and chemical company that looks for in-licensing products in late stage development or already in the market..
View profile© Copyright 1995-2009 Pharmalicensing, a division of UTEK Europe Ltd 
All rights reserved. Terms and Conditions | Contact us
